National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey  Stefan.

Slides:



Advertisements
Similar presentations
Active Crohn's disease is associated with low vitamin D levels
Advertisements

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Work disability in inflammatory bowel disease
The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and.
How do psychological variables influence coping strategies in inflammatory bowel disease?  Marta Iglesias-Rey, Manuel Barreiro-de Acosta, Francisco Caamaño-Isorna,
Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel 
Does the endoscopic appearance of the ileocecal valve suggest the severity of Crohn's disease in the terminal ileum?  Tamás Molnár, Klaudia Farkas, Ferenc.
Volume 115, Issue 3, Pages (September 1998)
Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody? 
Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events  Fernando Magro, Manuel.
YouTube® and inflammatory bowel disease
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report  Andreia Albuquerque, Fernando Magro,
Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature  Gurhan.
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis  Vincent Billioud, Alexander C. Ford,
High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference  Airi Jussila, Lauri J. Virta, Veikko Salomaa,
Disease severity does not affect the interval between IBD diagnosis and the development of CRC: Results from two large, Dutch case series  Erik Mooiweer,
Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD)  Mariam Aguas, Vicente Garrigues,
Association of a Nkx2-3 polymorphism with Crohn's disease and expression of Nkx2-3 is up-regulated in B cell lines and intestinal tissues with Crohn's.
Microscopic colitis patients have increased proportions of Ki67+ proliferating and CD45RO+ active/memory CD8+ and CD4+8+ mucosal T cells  Ashok Kumar.
Anterior ischemic optic neuropathy in a patient with Crohn's disease and aberrant MTHFR and GPIIIa gene variants  T. Felekis, K.H. Katsanos, C.D. Zois,
1 Patient enrollment flow chart.
Serum prohepcidin levels in chronic inflammatory bowel diseases
Oral tacrolimus for pediatric steroid-resistant ulcerative colitis
Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever  Nuray Uslu, Hulya Demir, Gunay Balta, Inci N Saltik-Temizel,
Charlotte de Bie, Angelika Kindermann, Johanna Escher 
N. Kjaersgaard Nielsen, V. Wewer, L. Skafte, A. Paerregaard 
Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever  Nuray Uslu, Hulya Demir, Gunay Balta, Inci N Saltik-Temizel,
Fatal Colonic Perforation in a Pregnant with Behçet's Disease
Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population- based cohort followed for ten years  May-Bente Bengtson, Camilla.
Public awareness of Crohn's disease and ulcerative colitis: A national survey  Sieglinde Angelberger, Harald Vogelsang, Gottfried Novacek, Wolfgang Miehsler,
B. Sicilia, F. Arribas, J. Nerín, C. López Miguel, R. Vicente, F
Incidence of ulcerative colitis and Crohn's disease in Danish children: Still rising or levelling out?  Christian Jakobsen, Vibeke Wewer, Frederikke Urne,
Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases  Danuta Owczarek,
Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature  Dana Duricova, Johan Burisch,
Edmonton, Canada: A Regional Model of Palliative Care Development
Paula Borralho, Ana Vieira, João Freitas, Paula Chaves, Jorge Soares 
Xian-rui Wu, Saurabh Mukewar, Ravi P. Kiran, Feza H
The usefulness of factor XIII levels in Crohn's disease
Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis  Niels Teich, Tobias Klugmann  Journal of.
Seth Lipka, Seymour Katz, Lev Ginzburg  Journal of Crohn's and Colitis 
Osteoporosis in inflammatory bowel disease
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis  M. De Vos, O. Dewit, G. D'Haens,
Pediatric pulmonary Crohn's disease: More frequent than expected
“Ulcerative crepitus” — A case with subcutaneous emphysema and pneumomediastinum without colonic perforation or toxic megacolon in ulcerative colitis.
Ulrich Bonse-Geuking, Michael Kraus  Journal of Crohn's and Colitis 
Increase in bone mineral density in strictly treated Crohn's disease patients with concomitant calcium and vitamin D supplementation  Sjoerd F. Bakker,
A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis  Urpo Kinnunen,
Association of a Nkx2-3 polymorphism with Crohn's disease and expression of Nkx2-3 is up-regulated in B cell lines and intestinal tissues with Crohn's.
Subrata Ghosh, Benjamin Pariente, Diane R
Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA- based protocol in UK subjects with inflammatory bowel disease suitable.
Does active smoking really influence the course of Crohn's disease
Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function  Ulf Hindorf, Malin Lindqvist.
Yinghong Wang, Hua Gong, Rocio Lopez, Lei Lian, Ravi P. Kiran, Edy E
Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab  Antonio López San Román, Manuel.
Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis  S.D. McLaughlin, A. Culkin,
Bowel sonography in occlusive Crohn's disease
Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors  Anilga Moradkhani, Linda.
Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.
Thys van der Molen, MD, PhD, Monica Fletcher, MSc, David Price, FRCGP 
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study  Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,
The Assessment of Cancer Pain in North India
Volume 150, Issue 5, Pages (May 2016)
U.S. Hospice Benefits Journal of Pain and Symptom Management
Volume 115, Issue 3, Pages (September 1998)
Charlene L. Taylor, RN, BSN  Journal of Pain and Symptom Management 
Meenakshi Bewtra, Chinyu Su, James D. Lewis 
S. Dahmani, H. Dupont, J. Mantz, J.M. Desmonts, H. Keita 
Seasonal variation in flares of inflammatory bowel disease
Presentation transcript:

National differences in ulcerative colitis experience and management among patients from five European countries and Canada: An online survey  Stefan Schreiber, Julián Panés, Edouard Louis, Derek Holley, Mandy Buch, Kristine Paridaens  Journal of Crohn's and Colitis  Volume 7, Issue 6, Pages 497-509 (July 2013) DOI: 10.1016/j.crohns.2012.07.027 Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

Figure 1 Ulcerative colitis severity rating across countries. (A) Patients' personal classification of ulcerative colitis severity: patients were asked how they would personally describe the severity of their ulcerative colitis overall, regardless of how their doctor described it. (B) Physicians' assessment of ulcerative colitis severity among their caseloads: physicians were asked what percentage of their current ulcerative colitis patients had mild, moderate, or severe disease. The data for each country may not always sum to 100% due to rounding. Journal of Crohn's and Colitis 2013 7, 497-509DOI: (10.1016/j.crohns.2012.07.027) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

Figure 2 Mean number of flares experienced (patient-defined), reported to a health care professional, and estimated by physicians (past 12months). Patients were asked how many flare‐ups of their ulcerative colitis they had experienced during the past 12months and how many of these flare‐ups they had discussed with their health care professional. The data for each country may not always sum to 100% due to rounding. Journal of Crohn's and Colitis 2013 7, 497-509DOI: (10.1016/j.crohns.2012.07.027) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

Figure 3 Most bothersome factor for patients, as assessed by patients and physicians. (A) Patients were asked which one of the following bothered them the most about their ulcerative colitis: urgency, pain, number of stools per day, blood in your stools, number of tablets to be taken, or none of the above. (B) Physicians were asked which one of the same choices they thought bothered their ulcerative colitis patients the most. The data for each country may not always sum to 100% due to rounding. Journal of Crohn's and Colitis 2013 7, 497-509DOI: (10.1016/j.crohns.2012.07.027) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

Figure 4 Patients' descriptions of what remission realistically means. Patients were asked which one of the following statements best described what remission realistically meant for them personally: (1) experiencing no symptoms, feeling similar to how I did before I developed ulcerative colitis; (2) living with some symptoms, but managing life without interruption; (3) living with symptoms and interruptions to daily life, but with less severity, pain, and bleeding as during a flare‐up; and (4) none of these. The data for each country may not always sum to 100% due to rounding. Journal of Crohn's and Colitis 2013 7, 497-509DOI: (10.1016/j.crohns.2012.07.027) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions

Figure 5 Estimation of disease control by patients and physicians (last 12months). (A) Patients were asked which one of the following statements best described how effectively their ulcerative colitis had been controlled over the past 12months: (1) my symptoms were completely or mostly under control; (2) my symptoms were present but did not interfere with my quality of life; (3) my symptoms caused some disruption to my quality of life; or (4) my symptoms affected my quality of life on a regular basis. (B) Physicians were asked (in terms of how effectively the patient' ulcerative colitis had been controlled over the last 12months) approximately what percentage of their mild‐to‐moderate ulcerative colitis patients fell into each of the following groups (see above statements). The data for each country may not always sum to 100% due to rounding. Journal of Crohn's and Colitis 2013 7, 497-509DOI: (10.1016/j.crohns.2012.07.027) Copyright © 2012 European Crohn's and Colitis Organisation Terms and Conditions